New imaging technology shows promise in detecting of spread of prostate cancer
https://www.facingourrisk.org/XRAY/new-screening-helps-to-detect-spread-of-prostate-cancer
Full article: https://meetinglibrary.asco.org/record/184099/abstract
A new imaging technique is currently being tested to see if it can detect the spread of prostate cancer sooner than standard imaging. Two clinical trials show that the new technique can detect the spread of prostate cancer in men who are newly diagnosed and in men whose cancer returns after treatment. (10/16/20)
Questions To Ask Your Health Care Provider
- What is the best way to tell if my prostate cancer has spread?
- What tests have already been done?
- What were the results of these tests?
- What, if any, additional testing should I have?
- Do these tests have any side effects?
- Is my prostate cancer low, intermediate or high risk?
- How will these tests affect my medical options?
- Can you provide a copy of my test results?
- Should I consider a clinical trial?
Open Clinical Trials
- NCT03860987: Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer. In this study researchers will combine abiraterone and enzalutamide to see if there is a better way to treat prostate cancer. They also want to study a new radiotracer called 18F-DCFPyL, with the help of a scan called positron emission tomography/computed tomography (PET/CT) to see if there is a better way to detect prostate cancer.
- NCT03181867: 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer. Current methods of imaging prostate cancer are limited. Researchers want to see if a radiotracer called 18F-DCFPyL can identify prostate cancer in patients who have a high risk of cancer spreading outside the prostate or who have signs of recurrent cancer after treatment.
- NCT03439033: Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer. This is a study primarily comparing Magnetic Resonance Imaging (MRI) alone to Positron Emission Tomography (PET)/MRI using an radioactive tracer among men with advanced prostate cancer or whose cancer has returned. Potential subjects who cannot undergo MRI may undergo PET/CT instead.
The following are studies looking at new methods for staging, monitoring and finding recurrence in people with prostate cancer.
- NCT02282137: 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer (PSMA). This study looks at the effectiveness of the 68Ga-PSMA-11 PET-CT scan to detect tumor location and measure size in patients with suspected or confirmed prostate cancer or prostate cancer that may have come back.
- NCT04030338: Prostate-Specific Membrane Antigen (PSMA) PET Scans to Find Prostate Cancer. This study will determine whether PET scans using PSMA are accurate and more effectively find prostate cancer than the standard methods.
- NCT04716725: 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer. This trial assesses whether using 68Ga-PSMA-11 PET scans will help doctors learn more about the location of disease in the body.
- NCT04777071: An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer. This trial studies how well 68Ga-PSMA-11 PET/CT scans work for imaging patients with prostate cancer.
- NCT04867603: Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions. This study evaluates a radioactive diagnostic drug called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) to determine whether prostate abnormalities are cancer.
- NCT05160597: Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy. This study looks at how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a PET/CT scan works in diagnosing prostate cancer in men with a prior negative or inconclusive prostate biopsy.
Several other clinical trials for monitoring patients with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.